<DOC>
	<DOCNO>NCT00225979</DOCNO>
	<brief_summary>Currently , first line treatment acromegaly surgery , order remove adenoma cause overproduction growth hormone lead acromegaly . The objective study ass safety efficacy long-acting repeatable formulation octreotide compare safety efficacy surgery patient acromegaly previous treatment acromegaly .</brief_summary>
	<brief_title>Safety Efficacy Long-acting Repeatable Octreotide Acetate Injectable Suspension v . Surgery Treatment-naïve Patients With Acromegaly</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Newly diagnose previously untreated acromegalic patient Lack suppression GH nadir &lt; 1.0 µg/L , oral administration 75 g glucose ( OGTT ) IGFI level upper limit normal , i.e . 97th percentile ( adjust age gender ) Requires surgery recent significant deterioration visual field neurological sign , relate pituitary tumor mass No evidence pituitary adenoma Magnetic Resonance Imaging ( MRI ) Symptomatic cholelithiasis Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Acromegaly</keyword>
	<keyword>Untreated</keyword>
	<keyword>Newly diagnose</keyword>
	<keyword>Octreotide LAR</keyword>
	<keyword>Pituitary surgery</keyword>
</DOC>